NFKB1 and metabolic dysfunction-associated steatohepatitis: Our findings showing CREBZF as a NF‐κB coregulator under overnutrition, coupling with the effects of CREBZF on exacerbated hepatic steatosis and NASH, suggest that targeting CREBZF may represent general benefits in treating metabolic diseases.